@article{oai:repo.qst.go.jp:00047113,
 author = {Eguchi, Haruki and Umemura, Masanari and Kurotani, Reiko and Fukumura, Hidenobu and Sato, Itaru and Kim, Jeong-Hwan and Hoshino, Yujiro and Lee, Jin and Amemiya, Naoyuki and Sato, Motohiko and Hirata, Kunio and J, Singh David and Masuda, Takatsugu and Yamamoto, Masahiro and Urano, Tsutomu and Yoshida, Keiichiro and Tanigaki, Katsumi and Yamamoto, Masaki and Sato, Mamoru and Inoue, Seiichi and Aoki, Ichio and Ishikawa, Yoshihiro and 青木 伊知男},
 journal = {Scientific reports},
 month = {Mar},
 note = {Research on controlled drug delivery for cancer chemotherapy has focused mainly on ways to deliver existing anti-cancer drug compounds to specified targets, e.g., by conjugating them with magnetic particles or encapsulating them in micelles. Here, we show that an iron-salen, i.e., μ-oxo N,N'- bis(salicylidene)ethylenediamine iron (Fe(Salen)), but not other metal salen derivatives, intrinsically exhibits both magnetic character and anti-cancer activity. X-Ray crystallographic analysis and first principles calculations based on the measured structure support this. It promoted apoptosis of various cancer cell lines, likely, via production of reactive oxygen species. In mouse leg tumor and tail melanoma models, Fe(Salen) delivery with magnet caused a robust decrease in tumor size, and the accumulation of Fe(Salen) was visualized by magnetic resonance imaging. Fe(Salen) is an anti-cancer compound with magnetic property, which is suitable for drug delivery and imaging. We believe such magnetic anti-cancer drugs have the potential to greatly advance cancer chemotherapy for new theranostics and drug-delivery strategies.},
 title = {A magnetic anti-cancer compound for magnet-guided delivery and magnetic resonance imaging.},
 volume = {5},
 year = {2015}
}